Meeting Report

Gynecologic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®


J Adv Pract Oncol 2022;13(6):603-609 | https://doi.org/10.6004/jadpro.2022.13.6.6 | © 2022 Harborside™


  

ABSTRACT

Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital/Brown University, interprets data presented at the 2022 ASCO Annual Meeting on rucaparib maintenance in advanced ovarian cancer, single-agent trabectedin in BRCA-positive ovarian cancer, tisotumab vedotin and pembrolizumab in cervical cancer, and patient selection for bevacizumab use in ovarian cancer.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.